Unlocking the Potential of UBE2V1P2: A novel Drug Target and Biomarker for Ubiquitin-Conjugating Enzyme E2

Target Name: UBE2V1P2

NCBI ID: G730052

UBE2V1P2

Other Name(s): Ubiquitin-conjugating enzyme E2 variant 1 pseudogene 2 | UBE2V1 pseudogene 2

Unlocking the Potential of UBE2V1P2: A novel Drug Target and Biomarker for Ubiquitin-Conjugating Enzyme E2

Introduction

Ubiquitin (UV) is a small non-covalent protein that plays a crucial role in regulating various cellular processes. It is composed of two subunits, E1 (UBE1) and E2 (UBE2), which function together to form a monomeric enzyme with a unique catalytic mechanism. Enzyme E2 (UBE2) is a key regulator of DNA double-strand break repair, and its dysfunction has been implicated in various diseases, including cancer, neurodegenerative disorders, and systemic inflammatory responses.

The Ubiquitin-conjugating enzyme E2 (UBE2) is a pseudogene that has been well conserved throughout evolution. It has been shown to play a critical role in the regulation of DNA double-strand break repair, DNA replication, and apoptosis. The E2 enzyme has four known variants: UBE2V1, UBE2V2, UBE2V3, and UBE2V4. UBE2V1P2 is one of the most well-studied variants, and its functions have been extensively characterized.

In this article, we will explore the potential of UBE2V1P2 as a drug target and biomarker. We will discuss the current state of research on UBE2V1P2, its potential therapeutic applications, and the challenges and opportunities in the development of new treatments.

Current Knowledge of UBE2V1P2

UBE2V1P2 has been extensively studied for its functions in DNA double-strand break repair and apoptosis. Several studies have shown that UBE2V1P2 plays a critical role in regulating the repair of double-strand breaks in damaged DNA. It has been shown to enhance the efficiency of DNA double-strand break repair by increasing the activity of the enzyme responsible for this process, N-end DNA-binding protein.

In addition to its role in DNA double-strand break repair, UBE2V1P2 has also been shown to regulate apoptosis, a critical intracellular process that helps eliminate damaged or dysfunctional cells. UBE2V1P2 has been shown to promote apoptosis by activating several cellular stress pathways, including the production of reactive oxygen species (ROS) and the activation of caspases.

Potential Therapeutic Applications

The therapeutic potential applications of UBE2V1P2 are vast and varied. One of the most promising avenues for research is the development of drugs that target UBE2V1P2 to treat various diseases, including cancer, neurodegenerative disorders, and systemic inflammatory responses.

In the context of cancer, UBE2V1P2 has been shown to promote the development and progression of various types of cancer. For example, several studies have shown that high levels of UBE2V1P2 are associated with poor prognosis in patients with colorectal cancer (3, 4). Moreover, UBE2V1P2 has been shown to promote the growth and survival of cancer cells, making it a potential target for cancer therapies.

In the context of neurodegenerative disorders, UBE2V1P2 has been shown to contribute to the development and progression of various neurodegenerative diseases. For example, UBE2V1P2 has been shown to promote the production of neurotoxins, such as amyloid peptides, in the brains of individuals with Alzheimer's disease. Additionally, UBE2V1P2 has been shown to modulate the activity of other neurodegenerative enzymes, such as 尾-secretase (7), which may play a role in the development and progression of these diseases.

In the context of systemic inflammatory responses, UBE2V1P2 has been shown to contribute to the development and maintenance of inflammatory diseases. For example, UBE2V1P2 has

Protein Name: UBE2V1 Pseudogene 2

The "UBE2V1P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBE2V1P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets